Focal Cryoablation Highlighted in Urology Times Best of AUA Orlando 2008
Noting the data presented at the annual meeting of the American UrologicalAssociation (AUA) in Orlando, the July issue of Urology Times captured andsummarized key take-home messages in 27 topic areas including "localizedprostate cancer." The publication highlighted "low rates of morbidity" thatresult from focal cryoablation.
Focal cryoablation outcomes reported on at the AUA's annual meetingincluded the first multi-center study of focal, or partial gland, cryoablationfor 341 prostate cancer patients. The study demonstrated that more than halfof the patients who were potent before the treatment were again potent aftersix months, and more than 74 percent resumed potency within 36 months.Patients in this study are part of the Cryo On-Line Database (COLD) Registrywhich contains records for more than 5,000 cryoablation procedures from 48physicians. This latest focal cryoablation study, the largest published thusfar, reported similar outcomes to earlier studies, some of which have followedpatients for up to 10 years with excellent long-term cancer control rates.
"Physicians and patients have struggled to find a middle ground betweenunder-treating prostate cancer, by 'watchful waiting,' and over-treatingthrough radical prostatectomy," said Endocare Chairman, CEO and PresidentCraig T. Davenport. "There is a growing body of evidence that focalcryoablation may be an effective option for men who want to considerdestroying localized focal cancer while at the same time preserving theirquality of life."
Also at the conference this year, the AUA for the first time ever adoptedan official set of clinical guidelines, or "best practices," for prostatecryoablation. These new guidelines, which included focal cryoablation, arefurther evidence of the growing acceptance of cryoablation within the urologyphysician community, Davenport noted.
Endocare, Inc. -- http://www.endocare.com -- is an innovative medicaldevice company focused on the development of minimally invasive technologiesfor tissue and tumor ablation. Endocare has initially concentrated ondeveloping technologies for the treatment of prostate cancer and believes thatits proprietary technologies have broad applications across a number ofmarkets, including the ablation of tumors in the kidney, lung and liver andpalliative intervention (treatment of pain associated with metastases).
Statements contained in this release that are not historical facts areforward-looking statements that involve risks and uncertainties. Among theimportant factors which could cause actual results to differ materially fromthose in the forward-looking statements include, but are not limited to, thosediscussed in "Risk Factors" in the Company's Forms 10-K, Forms 10-Q, and otherfilings with the Securities and Exchange Commission. Such risk factorsinclude, but are not limited to, uncertainty regarding the effects of thestudy described in this press release and any future studies and follow updata. The actual results that the Company achieves may differ materially fromany forward-looking statements due to such risks and uncertainties. TheCompany undertakes no obligation to revise
You May Also Like